Status:
COMPLETED
Tidal Volume in Patients With "de Novo" Acute Hypoxemic Respiratory Failure
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Acute Hypoxemic Respiratory Failure
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Protective ventilation can be difficult to achieve during noninvasive ventilation for "de novo"acute hypoxemic respiratory failure (i.e., not due to exacerbation of chronic lung disease or cardiac fai...
Eligibility Criteria
Inclusion
- Acute Respiratory Failure (ARF) ( 100 \<PaO2/FiO2 \<300) due to Covid-19 infection
- Informed consent
- Enrollment within the first 24 hours after ARF
Exclusion
- Clinical, radiological or istological evidence of chronic pulmonary disease.
- Body Mass Index (BMI) \> 30 kg/m2;
- Previous diagnosis of Obstructive sleep apnea syndrome (OSAS)
- Chest wall disease
- Heart failure
- Severe hemodynamic instability ( need for amine support)
- Acute coronary syndrome (ACS)
- Severe arrhythmia
- Patients unable to protect respiratory airways
- Respiratory arrest and need for endotracheal intubation
- Pregnancy
- Need for sedation
- Home long-term oxygen therapy
Key Trial Info
Start Date :
January 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2021
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04741659
Start Date
January 20 2021
End Date
July 30 2021
Last Update
November 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Policlinico di Sant'Orsola
Bologna, Italy, 40138